Recommended First-Line Treatment for Suspected DTR-PA with Severe AKI
For suspected difficult-to-treat resistant Pseudomonas aeruginosa (DTR-PA) infection in a patient with severe acute kidney injury, use ceftolozane-tazobactam as first-line therapy with dose adjustment for renal function, as this agent avoids the nephrotoxicity of polymyxins and aminoglycosides while maintaining efficacy against DTR-PA. 1
Rationale and Treatment Algorithm
Primary Recommendation
The 2022 ESCMID guidelines specifically recommend ceftolozane-tazobactam for severe DTR-PA infections when the organism is susceptible in vitro 1. This is particularly critical in severe AKI where nephrotoxic alternatives (polymyxins, aminoglycosides) pose unacceptable risks. The 2026 German guideline reinforces that ceftolozane-tazobactam is the preferred choice for DTR-PA 2.
Dosing Considerations in Severe AKI
Key principle: Beta-lactams require higher initial doses in critically ill patients, but severe AKI necessitates careful adjustment 3.
For ceftolozane-tazobactam in severe AKI:
- If CrCl 30-50 mL/min: 1.5 g (1 g ceftolozane/0.5 g tazobactam) every 8 hours
- If CrCl 15-29 mL/min: 750 mg (500 mg/250 mg) every 8 hours
- If on hemodialysis: Single loading dose of 750 mg, then 150 mg (100 mg/50 mg) every 8 hours
- If on CRRT: Dosing depends on effluent rate; typically 1.5-3 g every 8 hours
Administer via prolonged infusion (3-4 hours) to maximize time above MIC, especially for high-MIC organisms 3.
Alternative Agents (in order of preference if ceftolozane-tazobactam unavailable or resistant)
Ceftazidime-avibactam: Less nephrotoxic than older agents; dose adjust for AKI (1.25 g every 8h if CrCl 31-50; 0.94 g every 12h if CrCl 16-30) 1, 2
Imipenem-relebactam: Suitable for DTR-PA; requires renal dose adjustment 1, 2
Cefiderocol: Reserve for metallo-β-lactamase-producing strains; note the 2026 case report documenting treatment failure even with cefiderocol in pan-resistant strains 2, 4
Critical Pitfalls to Avoid
Do NOT use polymyxins (colistin) as first-line in severe AKI unless absolutely no other option exists. The evidence is compelling:
- Colistin-containing regimens caused acute kidney injury in 33.3% of patients versus only 10.7% when combined with fosfomycin 5
- Borderline colistin MICs (≥2 mg/L) show limited efficacy and high toxicity in AKI 4
- If polymyxin B must be used, fixed dosing (150 mg load, then 75 mg q12h) may be safer than weight-based dosing in preventing nephrotoxicity 6
Avoid aminoglycosides as monotherapy in severe AKI due to additive nephrotoxicity 1.
Combination Therapy Considerations
For severe DTR-PA infections, the guidelines cannot recommend for or against combination therapy with new beta-lactam/beta-lactamase inhibitors 1. However, if using older agents (polymyxins, aminoglycosides, fosfomycin), combination therapy with two active drugs is suggested 1.
If forced to use colistin due to resistance, add intravenous fosfomycin - this combination showed significantly reduced kidney injury (10.7% vs 33.3% with colistin alone) 5.
Monitoring Requirements
- Obtain rapid susceptibility testing including MIC determination
- Rule out metallo-β-lactamase production (changes treatment to cefiderocol or aztreonam-based regimens) 2
- Consider therapeutic drug monitoring for beta-lactams, targeting fCmin/MIC ratio of 4-8 (higher ratios increase neurotoxicity risk) 3
- Monitor renal function closely; doubling of creatinine or 50% GFR reduction indicates significant drug-related injury 5
Source Control
Ensure adequate source control regardless of antibiotic choice - no antibiotic regimen compensates for inadequate drainage or removal of infected devices 1.